vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and Limbach Holdings, Inc. (LMB). Click either name above to swap in a different company.
ANI PHARMACEUTICALS INC is the larger business by last-quarter revenue ($247.1M vs $186.9M, roughly 1.3× Limbach Holdings, Inc.). ANI PHARMACEUTICALS INC runs the higher net margin — 11.1% vs 6.6%, a 4.5% gap on every dollar of revenue. On growth, Limbach Holdings, Inc. posted the faster year-over-year revenue change (30.1% vs 29.6%). ANI PHARMACEUTICALS INC produced more free cash flow last quarter ($29.1M vs $27.9M). Over the past eight quarters, ANI PHARMACEUTICALS INC's revenue compounded faster (34.1% CAGR vs 25.3%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
Limbach Flugmotoren is a Chinese-owned company based in Germany that produces aircraft engines.
ANIP vs LMB — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $186.9M |
| Net Profit | $27.5M | $12.3M |
| Gross Margin | — | 25.7% |
| Operating Margin | 14.1% | 9.4% |
| Net Margin | 11.1% | 6.6% |
| Revenue YoY | 29.6% | 30.1% |
| Net Profit YoY | 367.5% | 25.0% |
| EPS (diluted) | $1.14 | $1.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $247.1M | $186.9M | ||
| Q3 25 | $227.8M | $184.6M | ||
| Q2 25 | $211.4M | $142.2M | ||
| Q1 25 | $197.1M | $133.1M | ||
| Q4 24 | $190.6M | $143.7M | ||
| Q3 24 | $148.3M | $133.9M | ||
| Q2 24 | $138.0M | $122.2M | ||
| Q1 24 | $137.4M | $119.0M |
| Q4 25 | $27.5M | $12.3M | ||
| Q3 25 | $26.6M | $8.8M | ||
| Q2 25 | $8.5M | $7.8M | ||
| Q1 25 | $15.7M | $10.2M | ||
| Q4 24 | $-10.3M | $9.8M | ||
| Q3 24 | $-24.2M | $7.5M | ||
| Q2 24 | $-2.3M | $6.0M | ||
| Q1 24 | $18.2M | $7.6M |
| Q4 25 | — | 25.7% | ||
| Q3 25 | — | 24.2% | ||
| Q2 25 | — | 28.0% | ||
| Q1 25 | — | 27.6% | ||
| Q4 24 | — | 30.3% | ||
| Q3 24 | — | 27.0% | ||
| Q2 24 | — | 27.4% | ||
| Q1 24 | — | 26.1% |
| Q4 25 | 14.1% | 9.4% | ||
| Q3 25 | 15.9% | 7.2% | ||
| Q2 25 | 6.6% | 7.5% | ||
| Q1 25 | 13.3% | 5.9% | ||
| Q4 24 | -2.3% | 9.1% | ||
| Q3 24 | -13.8% | 8.1% | ||
| Q2 24 | 3.7% | 6.7% | ||
| Q1 24 | 14.8% | 5.5% |
| Q4 25 | 11.1% | 6.6% | ||
| Q3 25 | 11.7% | 4.8% | ||
| Q2 25 | 4.0% | 5.5% | ||
| Q1 25 | 8.0% | 7.7% | ||
| Q4 24 | -5.4% | 6.9% | ||
| Q3 24 | -16.3% | 5.6% | ||
| Q2 24 | -1.7% | 4.9% | ||
| Q1 24 | 13.2% | 6.4% |
| Q4 25 | $1.14 | $1.01 | ||
| Q3 25 | $1.13 | $0.73 | ||
| Q2 25 | $0.36 | $0.64 | ||
| Q1 25 | $0.69 | $0.85 | ||
| Q4 24 | $-0.45 | $0.81 | ||
| Q3 24 | $-1.27 | $0.62 | ||
| Q2 24 | $-0.14 | $0.50 | ||
| Q1 24 | $0.82 | $0.64 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | $11.3M |
| Total DebtLower is stronger | — | $30.5M |
| Stockholders' EquityBook value | $540.7M | $195.7M |
| Total Assets | $1.4B | $381.1M |
| Debt / EquityLower = less leverage | — | 0.16× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $285.6M | $11.3M | ||
| Q3 25 | $262.6M | $9.8M | ||
| Q2 25 | $217.8M | $38.9M | ||
| Q1 25 | $149.8M | $38.1M | ||
| Q4 24 | $144.9M | $44.9M | ||
| Q3 24 | $145.0M | $51.2M | ||
| Q2 24 | $240.1M | $59.5M | ||
| Q1 24 | $228.6M | $48.2M |
| Q4 25 | — | $30.5M | ||
| Q3 25 | — | $56.3M | ||
| Q2 25 | — | $28.4M | ||
| Q1 25 | — | $23.7M | ||
| Q4 24 | — | $23.6M | ||
| Q3 24 | — | $20.5M | ||
| Q2 24 | — | $19.7M | ||
| Q1 24 | — | $19.4M |
| Q4 25 | $540.7M | $195.7M | ||
| Q3 25 | $505.8M | $181.6M | ||
| Q2 25 | $436.8M | $170.5M | ||
| Q1 25 | $418.6M | $161.1M | ||
| Q4 24 | $403.7M | $153.5M | ||
| Q3 24 | $405.9M | $142.2M | ||
| Q2 24 | $455.8M | $133.0M | ||
| Q1 24 | $452.0M | $125.5M |
| Q4 25 | $1.4B | $381.1M | ||
| Q3 25 | $1.4B | $409.1M | ||
| Q2 25 | $1.3B | $343.0M | ||
| Q1 25 | $1.3B | $336.4M | ||
| Q4 24 | $1.3B | $352.1M | ||
| Q3 24 | $1.3B | $324.4M | ||
| Q2 24 | $920.8M | $303.9M | ||
| Q1 24 | $914.5M | $289.2M |
| Q4 25 | — | 0.16× | ||
| Q3 25 | — | 0.31× | ||
| Q2 25 | — | 0.17× | ||
| Q1 25 | — | 0.15× | ||
| Q4 24 | — | 0.15× | ||
| Q3 24 | — | 0.14× | ||
| Q2 24 | — | 0.15× | ||
| Q1 24 | — | 0.15× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | $28.1M |
| Free Cash FlowOCF − Capex | $29.1M | $27.9M |
| FCF MarginFCF / Revenue | 11.8% | 14.9% |
| Capex IntensityCapex / Revenue | 0.5% | 0.1% |
| Cash ConversionOCF / Net Profit | 1.10× | 2.29× |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | $41.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $30.4M | $28.1M | ||
| Q3 25 | $44.1M | $13.3M | ||
| Q2 25 | $75.8M | $2.0M | ||
| Q1 25 | $35.0M | $2.2M | ||
| Q4 24 | $15.9M | $19.3M | ||
| Q3 24 | $12.5M | $4.9M | ||
| Q2 24 | $17.4M | $16.5M | ||
| Q1 24 | $18.3M | $-3.9M |
| Q4 25 | $29.1M | $27.9M | ||
| Q3 25 | $38.0M | $12.8M | ||
| Q2 25 | $71.8M | $1.2M | ||
| Q1 25 | $32.5M | $11.0K | ||
| Q4 24 | $13.5M | $18.0M | ||
| Q3 24 | $7.7M | $4.6M | ||
| Q2 24 | $13.0M | $13.2M | ||
| Q1 24 | $13.7M | $-6.5M |
| Q4 25 | 11.8% | 14.9% | ||
| Q3 25 | 16.7% | 7.0% | ||
| Q2 25 | 34.0% | 0.8% | ||
| Q1 25 | 16.5% | 0.0% | ||
| Q4 24 | 7.1% | 12.5% | ||
| Q3 24 | 5.2% | 3.4% | ||
| Q2 24 | 9.4% | 10.8% | ||
| Q1 24 | 10.0% | -5.5% |
| Q4 25 | 0.5% | 0.1% | ||
| Q3 25 | 2.7% | 0.3% | ||
| Q2 25 | 1.9% | 0.6% | ||
| Q1 25 | 1.3% | 1.7% | ||
| Q4 24 | 1.3% | 0.9% | ||
| Q3 24 | 3.2% | 0.3% | ||
| Q2 24 | 3.2% | 2.7% | ||
| Q1 24 | 3.3% | 2.1% |
| Q4 25 | 1.10× | 2.29× | ||
| Q3 25 | 1.66× | 1.52× | ||
| Q2 25 | 8.87× | 0.26× | ||
| Q1 25 | 2.23× | 0.22× | ||
| Q4 24 | — | 1.96× | ||
| Q3 24 | — | 0.66× | ||
| Q2 24 | — | 2.77× | ||
| Q1 24 | 1.00× | -0.52× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
LMB
| Owner Direct Relationships Segment | $145.0M | 78% |
| General Contractor Construction Manager Relationships Segment | $41.9M | 22% |
